EA201491153A1 - КОМПОЗИЦИИ БУПРЕНОРФИНА И АНТАГОНИСТОВ μ-ОПИОИДНЫХ РЕЦЕПТОРОВ - Google Patents

КОМПОЗИЦИИ БУПРЕНОРФИНА И АНТАГОНИСТОВ μ-ОПИОИДНЫХ РЕЦЕПТОРОВ

Info

Publication number
EA201491153A1
EA201491153A1 EA201491153A EA201491153A EA201491153A1 EA 201491153 A1 EA201491153 A1 EA 201491153A1 EA 201491153 A EA201491153 A EA 201491153A EA 201491153 A EA201491153 A EA 201491153A EA 201491153 A1 EA201491153 A1 EA 201491153A1
Authority
EA
Eurasian Patent Office
Prior art keywords
buprenorphine
opioid receptors
antagonists
compositions
antagonist
Prior art date
Application number
EA201491153A
Other languages
English (en)
Other versions
EA030609B1 (ru
EA030609B8 (ru
Inventor
Дэниел Дивер
Эллиот Эрич
Original Assignee
Алкермес Фарма Айэленд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алкермес Фарма Айэленд Лимитед filed Critical Алкермес Фарма Айэленд Лимитед
Publication of EA201491153A1 publication Critical patent/EA201491153A1/ru
Publication of EA030609B1 publication Critical patent/EA030609B1/ru
Publication of EA030609B8 publication Critical patent/EA030609B8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к композиции, содержащей бупренорфин и антагонист μ-опиоидных рецепторов, при этом указанная композиция характеризуется индексом активности агониста-антагониста (AAnAI), составляющим от примерно 0,7 до примерно 2,2; при этом
EA201491153A 2011-12-15 2012-12-14 Композиции бупренорфина и антагонистов мю-опиоидных рецепторов EA030609B8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (3)

Publication Number Publication Date
EA201491153A1 true EA201491153A1 (ru) 2015-04-30
EA030609B1 EA030609B1 (ru) 2018-08-31
EA030609B8 EA030609B8 (ru) 2018-10-31

Family

ID=47757653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491153A EA030609B8 (ru) 2011-12-15 2012-12-14 Композиции бупренорфина и антагонистов мю-опиоидных рецепторов

Country Status (24)

Country Link
US (8) US8822488B2 (ru)
EP (3) EP3153171B1 (ru)
JP (2) JP6038170B2 (ru)
KR (1) KR101996108B1 (ru)
CN (2) CN106727562B (ru)
AU (1) AU2012351806C1 (ru)
BR (1) BR112014012409B8 (ru)
CA (1) CA2858812C (ru)
CY (1) CY1121081T1 (ru)
DK (1) DK3153171T3 (ru)
EA (1) EA030609B8 (ru)
ES (2) ES2692771T3 (ru)
HR (1) HRP20181950T1 (ru)
HU (1) HUE041883T2 (ru)
IL (1) IL232785B (ru)
LT (1) LT3153171T (ru)
MX (1) MX2014007042A (ru)
PL (1) PL3153171T3 (ru)
PT (1) PT3153171T (ru)
RS (1) RS58322B1 (ru)
SI (1) SI3153171T1 (ru)
TR (1) TR201815154T4 (ru)
WO (1) WO2013088243A1 (ru)
ZA (1) ZA201405029B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010326676B2 (en) 2009-12-04 2013-03-14 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP6038170B2 (ja) 2011-12-15 2016-12-07 アルカーメス ファーマ アイルランド リミテッド ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
AU2016215432B2 (en) 2015-02-02 2020-07-30 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (ru) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
AR005423A1 (es) 1996-01-10 1999-06-23 Smithkline Beecham Spa Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EP1353909B1 (en) 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
DK1485051T3 (da) * 2002-03-20 2008-09-08 Euro Celtique Sa Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
NZ551288A (en) 2004-05-14 2010-10-29 Janssen Pharmaceutica Nv Carboxamido opioid compounds that are derivatives of tramadol
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
CA2587074C (en) 2004-11-05 2012-09-04 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
SI1856093T1 (sl) 2005-03-02 2010-03-31 Nycomed Gmbh Hidrokloridna sol R aR bR dimetoksipiridin il etoksi metoksi a b heksahidrofenantridin ola
JP2010522198A (ja) 2007-03-19 2010-07-01 アカドイア プハルマセウチカルス インコーポレーテッド ５−ｈｔ２ａインバースアゴニスト及びアンタゴニストの抗精神病薬との併用
EA020658B1 (ru) 2007-08-09 2014-12-30 Ренссилэйер Политекник Инститьют Четвертичные опиоидные карбоксамиды
JP2011512360A (ja) * 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
JP5555890B2 (ja) * 2009-03-19 2014-07-23 アルカーメス ファーマ アイルランド リミテッド 高い経口バイオアベイラビリティを有するモルフィナン誘導体
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
AU2010326676B2 (en) * 2009-12-04 2013-03-14 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP6038170B2 (ja) * 2011-12-15 2016-12-07 アルカーメス ファーマ アイルランド リミテッド ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物
WO2014190271A2 (en) * 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms

Also Published As

Publication number Publication date
CN106727562A (zh) 2017-05-31
BR112014012409B1 (pt) 2022-08-23
CN106727562B (zh) 2019-07-05
AU2012351806B2 (en) 2016-03-10
LT3153171T (lt) 2018-12-10
CA2858812C (en) 2019-02-26
US8822488B2 (en) 2014-09-02
ZA201405029B (en) 2015-10-28
NZ624056A (en) 2016-07-29
US9918978B2 (en) 2018-03-20
CN104159586A (zh) 2014-11-19
EP3153171A1 (en) 2017-04-12
EP3415148A1 (en) 2018-12-19
EP3153171B1 (en) 2018-09-19
US20190247387A1 (en) 2019-08-15
RS58322B1 (sr) 2019-03-29
KR101996108B1 (ko) 2019-10-01
US20130190342A1 (en) 2013-07-25
PL3153171T3 (pl) 2019-02-28
BR112014012409A2 (pt) 2017-06-13
DK3153171T3 (en) 2018-11-19
IL232785A0 (en) 2014-07-31
HRP20181950T1 (hr) 2019-03-22
EP2790702B1 (en) 2020-04-01
PT3153171T (pt) 2018-11-16
US10188643B2 (en) 2019-01-29
CY1121081T1 (el) 2019-12-11
EA030609B1 (ru) 2018-08-31
US10806731B2 (en) 2020-10-20
JP6403726B2 (ja) 2018-10-10
US9498474B2 (en) 2016-11-22
CA2858812A1 (en) 2013-06-20
IL232785B (en) 2021-04-29
WO2013088243A1 (en) 2013-06-20
KR20140107258A (ko) 2014-09-04
MX2014007042A (es) 2015-01-22
JP2016222706A (ja) 2016-12-28
US20160256450A1 (en) 2016-09-08
JP6038170B2 (ja) 2016-12-07
US20180078543A1 (en) 2018-03-22
HUE041883T2 (hu) 2019-06-28
BR112014012409B8 (pt) 2022-09-13
US20170056392A1 (en) 2017-03-02
US20150051240A1 (en) 2015-02-19
US20210196703A1 (en) 2021-07-01
TR201815154T4 (tr) 2018-11-21
AU2012351806A1 (en) 2014-05-15
EA030609B8 (ru) 2018-10-31
EP2790702A1 (en) 2014-10-22
US10314838B2 (en) 2019-06-11
JP2015505853A (ja) 2015-02-26
ES2692771T3 (es) 2018-12-05
AU2012351806C1 (en) 2016-06-16
US20180078542A1 (en) 2018-03-22
US9913837B2 (en) 2018-03-13
ES2791764T3 (es) 2020-11-05
SI3153171T1 (sl) 2019-01-31

Similar Documents

Publication Publication Date Title
EA201491153A1 (ru) КОМПОЗИЦИИ БУПРЕНОРФИНА И АНТАГОНИСТОВ μ-ОПИОИДНЫХ РЕЦЕПТОРОВ
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
EA201490037A1 (ru) Антагонисты trpv4
ECSP12012221A (es) Anticuerpos anti-cd40
EA201590534A1 (ru) Новые бициклические производные
PH12014502452A1 (en) Gip-glp-1 dual agonist compounds and methods
EA201390422A1 (ru) Бупренорфиновые аналоги
DK2726090T3 (da) Argininfri tnfr: fc-fusionspolypeptidsammensætninger
EA201590887A1 (ru) Композиция
NZ604510A (en) Dilutable biocidal compositions and methods of use
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201390467A1 (ru) Композиции антител и способы применения
DK2606042T3 (da) Disubstituerede tetrahydrofuranyl-forbindelser som antagonister af bradykinin-b1-receptor
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
EA201190260A1 (ru) Применение пропинеба в качестве средства для отпугивания птиц
UA110039C2 (xx) СПОЛУКИ 4-ЗАМІЩЕНОГО 3-ФЕНІЛСУЛЬФАНІЛМЕТИЛБІЦИКЛО$3.1.0]ГЕКСАНУ ЯК АНТАГОНІСТИ mGluR 2/3
WO2011091410A8 (en) Trpv4 antagonists
UY34099A (es) ?composición de agentes de coalescencia?.